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Cadmium is an environmental contaminant that enters the body usually 
through diet or cigarette smoke. Exposure to cadmium has been associated with 
the development of breast cancer. Recent studies have suggested that cadmium 
functions as an endocrine disruptor and mimics the actions of estrogen in breast 
cancer cells by activating the receptor (ER) to promote breast cancer cell 
growth. Although acute cadmium exposure is known to promote estrogen 
receptor-mediated gene expression associated with growth, the consequence of 
chronic cadmium exposure has been unclear. Since heavy metals are known to 
bioaccumulate, it is necessary to understand and elucidate the effects of 
prolonged, low-level cadmium exposure and its role in breast cancer progression. 
Therefore, this study aims to investigate the chronic effects of cadmium exposure 
on breast cancer progression. An MCF7 breast cancer cell line (MCF7-Cd) 
chronically exposed to 10-7M CdCl2 was developed and serves as a model 
system to facilitate studies on the effects of chronic cadmium exposure on breast 
cancer progression. The data presented here suggest that prolonged cadmium 
exposure results in the development of more aggressive cancer phenotypes 
increased cell growth, migration, and invasion. Cells exposed to cadmium were 
shown to express higher levels of SDF-1— a chemokine known to contribute to 
cancer cell growth, migration and invasion. Results from this study demonstrated 
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that the expression of SDF-1 was not only dependent on ER but also on c-jun 
and c-fos, and the interactions between ER with c-jun and c-fos were 
significantly increased at both the protein and transcription levels in cells 
chronically exposed to cadmium. Additionally, the data showed that chronic 
cadmium exposure was able to disrupt cell-cell adhesion by down-regulating E-
cadherin expression, which led to relocation of active -catenin to the nucleus, 
and in turn led to increased metastasis and invasion. The work presented here 
provides a mechanistic link between chronic cadmium exposure, ER, and 
breast carcinogenesis and demonstrates that prolonged cadmium exposure, 
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1.1  Breast Cancer 
Breast cancer is one of the most common malignancies that occurs in 
women in the United States and accounts for 1 in 4 female cancers.  It is the 2nd 
leading cause of cancer-related deaths in women after lung cancer (ACS 2012). 
In 2011 approximately 230,480 cases of invasive breast cancer were diagnosed 
compared to 57,650 in situ breast cancer cases (ACS 2011). Approximately 
39,510 women and 410 men in 2012 are expected to die from breast cancer, with 
the majority of the cases categorized as invasive breast cancer (ACS 2012). 
Over the past several decades, the global incidence rates of breast cancer have 
increased continuously, and it is estimated that approximately 1 in 8 women in 
the United States will develop invasive breast cancer (ACS 2012). 
Breast cancer is multi-factorial, which makes it difficult to pin-point a single 
cause or target for its initiation, and complicates the ability to treat and 
understand the disease (Richie and Swanson 2003, Althuis et al. 2005).  Multiple 
risk factors are associated with breast cancer development, both biological and 
environmental. Biological risk factors include, but are not limited to, gender, age, 
family history, and age of menarche and menopause. Environmental risk factors 
include, but are not limited to, lifestyle habits and exposure to radiation, 
carcinogens, phytoestrogens, xenoestrogens, organohalogens and pesticides. 
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Epidemiological studies have shown that 90% of breast cancer cases are 
environmental in origin (Lipworth 1995, Harvey and Darbre 2004, Darbre 2006).   
A large number of epidemiological and experimental studies have 
indicated a role for estrogens in the etiology of human breast cancer (Henderson 
et al. 1982, Henderson et al. 1988, Feigelson et al. 1996, Henderson and 
Feigelson 2000). This is why life-time exposures to estrogen are considered a 
major risk factor in breast cancer. Estrogens are produced in the female ovaries 
and play an important role in developmental processes, promoting growth and 
differentiation of sex tissues and reproductive organs. There are three circulating 
forms of estrogens in the body: estrone, estradiol, and estriol, with estradiol being 
the major and most active form of estrogen. Estriol is produced in large quantities 
by the placenta in pregnant women, and estrone is produced mainly in post-
menopausal women. In addition, estrogens also play a pivotal role in brain 
function, bone maintenance, and accumulation of adipose tissue (Bryne et al. 
2009). Finally, there is clear evidence that estrogen exposure is a key contributor 
to the development of breast cancer, partly through its ability to stimulate the 
growth of mammary epithelial cells (Eliassen et al. 2006, Henderson and 
Feigelson 2000, Henderson et al. 1988). 
  
1.2 The Estrogen Receptor 
The actions of estrogens in the breast are primarily mediated by two 
nuclear estrogen receptors, ER and ER, and by GPR30 (GPER), a G-protein 
coupled receptor found in the membrane. Estrogen receptors are part of a super 
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family of nuclear hormone receptors that function as ligand-activated 
transcription factors. ER and ER are isoforms and share more than 97% and 
59% homology in their DNA binding and ligand binding domains, respectively; 
however, they are highly variable in their NH2-terminal transactivation AF-1 
domains (Mosselman et al. 1996, Paech et al. 1997, Aquino et al. 2012). The 
DNA binding domain contains well-conserved cysteine-rich regions which 
tetrahedrally coordinate with zinc ions to form two zinc finger motifs. The C-
terminal domain is the most complex region, both structurally and functionally. It 
is responsible for receptor dimerization and ligand-specific gene transcription 
mediation (Yang et al. 2008, Montano et al. 1995, Koide et al. 2007).  
While ER and ER share similar ligand-dependent transactivation 
functions, it appears that they play distinct roles in the development and 
progression of breast cancer. Studies have suggested that ER mediates the 
mitogenic actions of estrogen and ER mediates the anti-mitogenic effects 
(Pettersson and Gustafsson 2001).  In support of this, Pettersson et al. studied 
mammary glands from ER knockout mice and compared them to mammary 
glands from wild-type mice. Their results showed that the tissues in both animal 
types were indistinguishable, although the mammary glands from ER knockout 
mice were found to be underdeveloped when compared to wild-type ER mice. 
From his results, Pettersson concluded that ER mediates mitogenic effects 
(Pettersson et al. 2001). The role of ER remains unclear. Some studies suggest 
that high levels of ER expression are indicative of more advanced breast cancer 
tumors while other studies show that ER might play a protective role in breast 
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cancer (Clarke et al. 2003, Bardin et al. 2004, Lazennec et al. 2001, Hodges-
Gallagher et al. 2008, Jarvinen et al. 2000, Nair et al. 2012). Since ER’s role in 
mediating the mitogenic effects of estrogens is important in breast 
carcinogenesis, it serves as an important prognostic marker of the disease. 
GPR30 is a seven-transmembrane receptor found in the plasma 
membrane and endoplasmic reticulum (Thomas et al. 2005, Filardo et al. 2006, 
Revankar et al. 2005). Activation of GPR30 upon binding to estrogen leads to 
rapid intracellular signaling by activation of a downstream  signaling cascade, 
that includes activation of epidermal growth factor (EGFR) and subsequent 
increase of cyclic AMP, resulting in activation of transcriptional activity necessary 
for proliferation (Filardo et al. 2000, Filardo et al. 2006, Maggiolini et al. 2004). 
The role of GPR30 in breast cancer remains unclear due to contradictory 
findings. GPR30 has been shown to be expressed in invasive ductal carcinomas 
(Liu et al. 2009) and shown to induce breast cancer cell proliferation and 
migration in vitro (Pandey et al. 2009, Madeo and Maggiolini 2010). However, 
GPR30 has also been shown to be involved in apoptosis and cell cycle arrest 
(Teng et al. 2008, Wang et al. 2008, Ariazi et al. 2010).  
Seventy percent of primary breast cancer tumors are ER-positive, and 
two-thirds of these respond to endocrine therapy utilizing anti-estrogens (i.e. 
tamoxifen) (Hanstein et al. 2004, Giacinti et al. 2006).  While a majority of the 
ER positive breast cancers respond well to anti-estrogens, a fraction of the 
treated tumors become de-sensitized, resistant to tamoxifen.  These resistant 
cancers are often more aggressive, and in some cases, tamoxifen treatments 
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have been shown to further stimulate cancer growth (Hiscox et al. 2005, Clarke 
et al. 1993).  
ER has been shown to interact with a group of proteins referred to as 
nuclear receptor regulators which include co-activators and co-repressors 
(Benecke et al. 2000, Robyr et al. 2000, McKenna and O’Malley 2002). 
Recruitment of steroid receptor co-activators is required for full transcriptional 
activity of ER. Examples of coactivators include the p160 family of steroid 
receptor coactivators SRC-1, SRC-2, SRC-3, and p300/CBP (Chen et al. 1997, 
Han et al. 2009). Some of these co-regulators possess histone acetyltransferase 
activity which contributes to chromatin remodeling and thus can lead to further 
enhancement of ERα-mediated transactivator activity (Chen et al. 1997, Lu and 
Danielsen 1998, Kishimoto et al. 2005). A study by Kishimoto et al. further 
demonstrated the importance of co-activator recruitment for estrogen-induced 
expression of SDF-1, cathepsin D (CTD) and c-myc, and their results showed 
that coactivator binding is necessary for the expression of these ER targets.  
Interestingly, these ERα genes (SDF-1, CTD and c-myc) are also involved in 
breast cancer proliferation, invasion, and metastasis (Kishimoto et al. 2005). 
 
1.3  Endocrine disruptors and Metalloestrogens 
The development of the breast from puberty through cycles of pregnancy and 
lactation is controlled by an intricate web of hormone signaling pathways (Darbre 
2006). Among these hormone pathways, estrogen signaling is the major pathway 
controlling the development of the mammary gland. The importance of estrogens 
5
in the etiology of breast cancer suggests that exposures to environmental or 
man-made compounds or chemicals (i.e. endocrine disruptors)— which mimic 
the effects of estrogen and alter the estrogen receptor signaling pathway— are 
potential risk factors for the disease (Colborn et al. 1993). Endocrine disruptors 
can be either man-made or naturally present in the environment, and some 
common endocrine disruptors include pharmaceutical estrogens found in 
contraceptives or hormone replacement therapy, phytoestrogens found in 
soybeans, xeno-estrogens (man-made chemicals with estrogenic activity), and 
metalloestrogens.  
 
1.4  The Metalloestrogen Cadmium 
Metalloestrogens are a group of heavy metals which mimic the actions of 
estrogen. Metalloestrogens include heavy metals and metalloids such as 
aluminum, nickel, cadmium, antimony, cobalt, copper, tin, vanadate, lead, 
mercury, arsenite, barium, chromium, selenite, nitrate and uranium (Garcia-
Morales et al. 1994, Stoica et al. 2000a,b,c, Johnson et al. 2003, Martin et al. 
2003, Darbre 2005, Choe et al. 2003, Raymond-Whish et al. 2007, Veselik et al. 
2008). Exposure to some heavy metals has been associated with an increased 
incidence of breast cancer development (Choe et al. 2003, Martin et al. 2003). 
Of all the metalloestrogens, cadmium is the best characterized.  Cadmium is 
widely used in industry for the production of alloys, nickel-cadmium batteries, 
fertilizers, pigments and plastic stabilizers. Occupationally, individuals are 
exposed to cadmium through the production and processing of cadmium, the 
6
refining and use of copper and nickel, fossil fuel combustion, and the recycling of 
electronic waste. Cadmium is found as a natural component of the Earth’s crust 
and is present in the atmosphere; however, it is important to note that the 
production and processing of cadmium adds 3-10 times more cadmium to the 
atmosphere than natural sources (Irwin et al. 1997). Among non-occupationally 
exposed individuals, exposure to cadmium occurs primarily from cigarette 
smoke. For non-smoking, non-occupationally exposed individuals, exposure to 
cadmium arises mostly from dietary sources due to the high rates of transfer of 
cadmium from soils to plants (Clemens 2006, Franz et al. 2008, McLaughlin et al. 
2006, Satarug et al. 2010). Therefore, exposure to cadmium occurs daily through 
contaminated food, water, and air. 
Once absorbed into the body, cadmium is rapidly transported to various 
organs and has an estimated half-life of 15-20 years in humans (Jin et al. 1998, 
Satarug et al. 2003).  Heavy metals like cadmium tend to accumulate in soft 
tissues of the body (Islam et al. 2007), and this accumulation often interferes with 
normal physiological functions by disrupting protein folding and/or activity. The 
chemical properties of cadmium allow it to combine easily with oxidized ligands, 
particularly those containing sulfur, which are a major component of many 
biological molecules including proteins. Additionally, due to the similar 
coordination chemistry of zinc and cadmium, zinc is often displaced by cadmium 
in many proteins and enzymes (Martelli et al 2006). Cadmium has also been 
shown to induce chromosomal aberrations, aneuploidy, sister chromatid 
exchanges, and to induce DNA strand breaks and DNA-protein crosslinks in 
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mammalian cells (Seoane and Dulout 2001, Ochi and Oshawa 1985, Lin et al. 
1994, Ochi and Oshawa 1983, Misra et al. 1998, Fatur et al. 2002, Liu and Jan 
2000). Furthermore, cadmium has been shown to inhibit DNA repair, activate 
proto-oncogenes (i.e. c-myc, c-jun, and c-fos) and genes associated with cell 
proliferation (i.e. cyclin D1), and inhibit apoptosis, all of which can contribute to 
the development and progression of breast cancer (Hartwig  1998, Abshire et al. 
1996, Zheng et al. 1996, Shimada et al. 1998 Martelli et al. 2006, Siewit et al. 
2010). 
   
1.5  Cadmium and Breast Cancer  
The International Agency for Research on Cancer and the National 
Toxicology Program of the United States of America have classified cadmium as 
a category I human carcinogen (IARC 1993, NTP 2011) because increasing 
evidence shows both occupational and non-occupational exposure to cadmium 
are associated with cancers of the lung, prostate, pancreas, kidney, liver, 
stomach, and urinary bladder (Waalkes and Rehm 1994, Schwartz and Reis 
2000, Pesch et al. 2000, Hu et al. 2002, Waalkes et al. 2000, Waalkes et al. 
1999, Satarug et al. 2010, Akesson et al. 2008, Ursin et al. 1994).  Cadmium 
exposure has also been correlated with an increase in the incidence of breast 
cancer (Cantor et al. 1994, Martin et al. 2003, Choe et al 2003). 
Several studies have shown that cadmium has the ability to mimic biological 
functions of estrogen in breast cancer cells by activating the estrogen receptor 
(Martin et al. 2003, Bryne et al. 2009 Garcia-Morales et al. 1994, Stoica et al. 
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2000, Johnson et al. 2003, Siewit et al. 2010). Previous work from our lab and 
others has suggested that cadmium can promote breast cancer cell growth in 
MCF-7 cells via ER (Siewit et al 2010, Martin et al. 2003, Garcia-Morales et al. 
1994). Animal studies have suggested that cadmium can mimic the role of 
estrogen in vivo and promote neoplastic growth, increase uterine weight, induce 
changes in the uterine lining, and increase the density of mammary glands in rats 
and mice (Johnson et al. 2003, Hofer et al. 2009, Ali et al. 2010, Alonso-
Gonzales et al. 2007). Collectively, these studies demonstrate that cadmium 
functions as a hormone-disruptor and metalloestrogen and is an important 
contributor to the development of breast cancer. 
Recent studies have identified significantly higher levels of cadmium in 
tumor tissues as well as in biological samples from tumor patients (Ionescu et al. 
2006, Strumylaite et al. 2008, Satarug et al. 2010; Strumylaite et al. 2011). 
Specifically, Strumylaite et al. measured and compared cadmium concentrations 
in biological samples from patients with breast cancer and benign breast tumors 
and found that patients with malignant cancer had significantly higher levels of 
cadmium concentrations when compared to patients with either benign tumors or 
estrogen receptor-negative cancers (Strumylaite et al. 2011), offering further 
support for a possible relationship between cadmium and ER. Accumulating 
evidence links exposures of environmental estrogens to an increased incidence 
of cancer (Satarug et al. 2010, Akesson et al. 2008, Ursin et al. 1994, Cantor et 
al. 1994). 
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Most studies have only examined the effects of acute cadmium 
exposures, and few studies have focused on the effects of chronic cadmium 
exposure on breast cancer progression. Cancer progression is often marked by 
the development of more aggressive phenotypes (Hanahan and Weinberg 2000), 
and the role of chronic cadmium exposure in this process requires further 
investigation. A recent study has demonstrated that chronic cadmium exposure 
can transform normal breast epithelial cells, MCF10A cells, into a malignant-
appearing form. These exposed MCF10A cells displayed more aggressive 
cancer-like characteristics, including an increased ability to grow in an 
anchorage-independent manner and the ability to invade the extracellular matrix 
through an increase in cellular expression of matrix metalloproteinase-9 (MMP-
9), an enzyme which facilitates tumor cell invasion (Bembrahim-Tallaa, et al. 
2009). Furthermore, when these transformed cells were implanted in nude mice, 
they formed highly aggressive tumors, further demonstrating the increased 
metastatic potential of cells chronically exposed to cadmium. Understanding the 
molecular mechanisms involved in the role of chronic cadmium exposure during 
breast carcinogenesis should provide further insights into how chronic 
environmental exposures may contribute to disease development and 
progression.  Our lab is focused on investigating how chronic cadmium exposure 
contributes to the progression of breast cancer, specifically focusing on two 
genes, SDF-1 and CDH-1. Although there are studies on the relationship 
between SDF-1 and CDH-1 (Rhodes et al. 2011, Wang et al. 2011) and cancer 
progression, few to no studies have been done on the molecular connection 
10
between cadmium and SDF-1 and cadmium and CDH1 (Park et al. 2008, 
Pearson and Prozialeck 2001). 
 
1.6 SDF-1 and Breast Cancer Metastasis 
Stromal derived factor-1 (SDF-1)— also known as CXCL12— is a novel 
estrogen receptor-regulated gene and a mediator of mitogenic effects. It can 
mimic the proliferative effects of estrogen in a dose-dependent manner in breast 
and ovarian cells (Hall and Korach 2003, Kishimoto et al. 2005). SDF-1 is one of 
the 40 to 50 human chemokines— small molecular weight proteins characterized 
by the ability to stimulate chemotaxis (Vacari and Caux 2002). Chemokines are 
considered pro-inflammatory and regulate cell trafficking and immune response 
to recruit macrophages and other immune cells to sites of infection (Vacari and 
Caux 2002). However, chemokines like SDF-1 have been reported to be 
expressed in many tumor cell types and have a direct tumor growth effect 
(Rollins 1997, Rossi and Zlontnik 2000, Vacari and Caux 2002). Additionally, 
SDF-1 and the family of chemokines are involved in growth, invasion and 
orchestrating events that result in primary tumor growth, invasion and metastasis 
(Vicari and Caux 2002).  SDF-1 can induce the production of metalloproteinases 
(MMPs), enzymes which degrade the extracellular matrix to promote the invasive 
behavior of breast cancer cells (Williams et al. 2010, Jezierska and Motyl 2009), 
and facilitate metastasis. Metastasis occurs when a malignant cell has the ability 
to detach from its original tumor and travel to distant sites to form secondary 
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tumor foci. One mechanism that cancer cells can achieve this is by disrupting 
cell-to-cell adhesion complexes to facilitate malignant cell detachment.  
 
1.7 E-Cadherin and Breast Cancer Metastasis 
E-cadherin, otherwise known as CDH-1, is a Ca2+-dependent 
transmembrane glycoprotein that plays a major role in cell-to-cell adhesion 
(Pearson and Prozialeck 2001, Baranwal and Alahari 2009, Jiang and Mansel 
2000). The cell-to-cell adhesion complexes are composed of E-cadherin linked to 
the actin cytoskeleton through a group of molecules called catenins (i.e. -
catenin). -catenin, a member of the E-cadherin/-catenin complex, is not only 
involved in cell signaling and transcriptional regulation but is also a regulator of 
cell adhesion (Jiang and Mansel, 2000). E-cadherin a tumor suppressor protein 
and is often used as a prognostic marker for breast cancer (Heimann and 
Hellman 2000, Baranwal and Alahari 2009). Down-regulation of E-cadherin has 
been associated with more aggressive breast cancers and poor prognosis 
(Mohammadizadeh et al. 2009, Oka et al. 1993). A decrease or loss of E-
cadherin expression could be due to genetic or epigenetic alterations. Genetic 
inactivation of E-cadherin is due to mutations and/or loss of heterozygosity in 
chromosome 16q22.1 and is reported to be associated with gastric carcinomas, 
gynecologic cancers, hepatocellular carcinomas, and breast carcinomas (Natt et 
al. 1989, Sato et al. 1990, Becker et al. 1994, Risinger et al. 1994, Kanai et al. 
1994, Berx et al. 1995, Tsuda et al. 1990). Epigenetic inactivation of E-cadherin 
can also result from DNA methylation (Yoshiura et al. 1995, Graff et al. 1995). 
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Specifically, methylation of the E-cadherin promoter has been associated with 
many human cancer types and often results in decreased expression of E-
cadherin and subsequent progression and metastasis of the disease (Nass et al. 
2000, Strathdee 2002).    
In this thesis, I will discuss how chronic cadmium exposure results in the 
deregulation of SDF-1 (Chapter 2) and E-cadherin (Chapter 3) and how this may 
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CHRONIC CADMIUM EXPOSURE STIMULATES SDF-1 EXPRESSION IN AN 
ER DEPENDENT MANNER 
 
2.1 Introduction 
  The majority of breast cancers initially develop as hormone-dependent, 
with estrogen receptors expressed in approximately 70% of breast cancer cases. 
The estrogen receptor is part of the super family of nuclear hormone receptors 
that function as ligand-gated transcription factors.  Two isoforms of the ER 
exist— ER and ER. These receptors play pivotal roles in cell differentiation, 
growth and homeostasis and function as molecular switches to modulate 
between states of transcriptional repression and activation, depending on the 
absence or presence of hormones. The two isoforms share considerable 
homology in their DNA binding domains and carboxyl terminal domains but are 
highly variable in their AF-1 amino terminal transactivation domains (Mosselman 
et al. 1996, Paech et al. 1997).  Although both ER and ER bind to 17-
estradiol with similar affinities and recognize the same consensus estrogen 
response element (ERE) in promoters of ER-regulated genes (Huang et al. 
2002), their roles in breast cancer are quite different.  While ER has long been 
established as an important player in promoting the development and 
progression of breast cancer, less is known about the role of ER in breast 
cancer progression. The presence or absence of ER is a key determinant of the 
prognosis of the disease as it determines whether the cancer will respond to 
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hormone therapy or not. ER-positive breast cancers are often hormone-
responsive and are typically treated with antiestrogens like tamoxifen. However, 
hormone-dependent breast cancer frequently progresses into more malignant 
cancer phenotypes that are often hormone-independent.  In many of these 
cases, ER is still present, and the role of ER in hormone refractory breast 
tumorigenesis and its underlying mechanism is unclear. A potential mechanism 
involves metalloestrogens: heavy metals that mimic the actions of estrogen and 
function as endocrine disruptors. 
As mentioned previously in Chapter 1, this study aims to further 
investigate the chronic effects of cadmium exposure on breast cancer 
progression. To this end, we developed a cadmium breast cancer cell line 
(MCF7-Cd) by chronically exposing MCF7 cells to 10-7 M CdCl2 for over 6 
months, and used it as a model system to study the effects of chronic cadmium 
exposure on breast cancer progression. This study provides several lines of 
evidence suggesting that prolonged cadmium exposure results in more 
aggressive cancer phenotypes such as increased cell growth, migration and 
invasion. These results also show that cells chronically exposed to cadmium 
express higher levels of SDF-1 and that this expression is not only dependent on 
ER but also on c-jun and c-fos members of the activating protein (AP)-1 family 
of transcription factors. The ERα/c-jun/c-fos interactions were significantly 
increased in cells chronically exposed to cadmium, with higher levels of ERc-
jun and c-fos occupying the SDF-1 promoter.  In summary, these results suggest 
that chronic cadmium exposure promotes more aggressive cancer phenotypes 
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by modifying the molecular interactions of ER with c-jun and c-fos thereby 
directly altering the expression of cancer-promoting genes like SDF-1. 
 
2.2 Materials and Methods 
Cell Culture 
MCF7 cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). MCF7-Cd was developed by exposing parental MCF7 cells to 
10-7 M CdCl2 for over 6 months. Parental MCF7 and MCF7-Cd were maintained 
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS; Hyclone, Logan, UT) and 1% penicillin and streptomycin 
(P/S). Both cell lines were subcultured every 3-4 days. 
 
Growth Assay 
The MCF7 and MCF7-Cd cells were plated at a cell density of 2.0x105 cells/well 
in six-well plates using hormone depleted media. Cells were counted in triplicate 
manually every 2 days using a hemocytometer. Data points represent three 
independent experiments.  
 
Derivation of cadmium cell lines 
To derive clonal cell lines chronically exposed to cadmium, MCF-7 cells were first 
exposed to 10-7M CdCl2 for over 6 months in order to mimic chronic exposures. 
Chronically exposed cells were plated on soft agar to allow single cells to 
develop into colonies. Briefly, a 1% agar solution made with complete media 
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(DMEM+10% FBS + 1% P/S) was used to create the bottom layer. Serial 
dilutions of single cell suspensions were mixed with enough complete media to 
make a 0.6% top agar that was added over the 1% bottom agar layer and 
allowed to solidify for 30 minutes at room temperature followed by incubation at 
37°C.  When colonies sizes reached about 100 cells or more, they were 
individually removed from soft agar under aseptic conditions and resuspended in 
complete media to permit further expansion.  
 
Scratch Wound Assay 
Approximately 2.0x104 cells were plated in 6-well plates and allowed to grow to 
approximately 75-80% confluency in DMEM. A wound, or scratch, was created 
with a 200μL micropipette tip. Cells were allowed to incubate for an additional 3 
days and images of the scratch area were captured digitally. 
 
Migration and Invasion Assay 
A modified Boyden chamber assay was used to quantitatively assess the cells’ 
migration and invasion abilities. For the migration assay, cells were hormone-
deprived, and 5.0x104 cells were seeded in the upper chamber over 
polycarbonate membrane inserts and allowed to migrate toward the lower 
chamber filled with DMEM+ 10% FBS+ 1% P/S. The cells were incubated for 12-
18 hours, fixed in formalin, and stained with crystal violet.  The number of cells 
that migrated to the underside of the filter was counted in triplicate.   For the 
invasion assay, a CytoSelectTM Cell Invasion Assay Kit (Cell Biolabs, Inc, San 
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Diego, CA) was used according to the manufacturer’s protocol. Briefly, 5.0x104 
hormone-deprived cells were seeded in the upper chamber and the cells that 




Cells were lysed in 1% SDS-HEPES buffer and the total protein concentration 
was normalized using the Bio-Rad Dc Protein Assay kit (Bio-Rad, Hercules, CA). 
Proteins were separated using SDS-polyacrylamide gel electrophoresis and 
transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, 
MA). Protein expression was monitored using protein-specific antibodies: -ERα 
(NeoMarkers, Fremont, CA), -cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, 
CA), -c-myc (Santa Cruz Biotechnology), -cyclin A (Santa Cruz 
Biotechnology), -cyclin E (Santa Cruz Biotechnology), -cdk2 (Santa Cruz 
Biotechnology), -cdk4 (BD Transduction Laboratories, San Jose, CA), -p21 
(Santa Cruz Biotechnology), -p-27 (Santa Cruz Biotechnology), -CDH1 (Santa 
Cruz Biotechnology), --catenin (Cell Signaling Technology, Danvers, MA), -
GAPDH (Cell Signaling Technology).  
 
SDF-1 ELISA  
Cells were plated at a density of 1x105 cells per well in 6-well plates. Cell culture 
media was collected after 48 hours and stromal cell-derived factor-1 (SDF-1) 
levels were measured with the enzyme-linked immunosorbent assay (ELISA) 
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SDF-1 kit (RayBiotech, Inc, Norcross, GA) according to the manufacturer’s 
instructions. Briefly, 100μL of sample was added to 96-well plates containing 
immobilized antibodies specific for human SDF-1 and allowed to incubate 
overnight with shaking at 4°C. Wells were then washed and a biotinylated anti-
human SDF-1 antibody was added, followed by another wash and subsequently 
by the addition of HRP-conjugated streptavidin. Following a final wash, 
tetramethylbenzidine (TMB) substrate for color development was added and 
samples were read at 450nm after the addition of a stop solution. 
 
siRNA Transfection 
Approximately 1x105 cells/well were plated in 6 well plates and transfected with 
siRNA (Santa Cruz Biotechnology) targeting either ER, c-jun or c-fos using 
siRNA transfection reagents (Santa Cruz Biotechnology).  A scrambled siRNA 
was transfected as a control. Five hours after transfection, the medium was 
changed to DMEM medium containing 10% FBS and 1% P/S.  Cells were 
harvested 48 hours later for gene and/or protein expression analysis using semi-
quantitative reverse transcription-polymerase chain reactions (RT-PCR) or 
quantitative RT-PCR (qRT-PCR), and Western blot analysis, respectively. 
 
Reverse Transcriptase Polymerase Chain Reaction (RT- PCR) 
Total RNA was isolated from cells using TRI-Reagent (Zymo Research 
Corporation, Irvine, CA) and columns from the Direct-zol RNA MiniPrep kit (Zymo 
Research) according to the manufacturer’s protocol. Three micrograms (g) of 
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total RNA were used for the reverse transcription reaction with oligo-dT18 primers 
and Moloney Murine Leukemia Reverse Transcriptase (M-MLV RT, Promega, 
Madison,WI). Gene expression was monitored using semi-quantitative PCR for 
28 cycles. PCR products were separated by agarose gel electrophoresis, and 
visualized using Chemi-Doc (Biorad). Gene expression was quantified using 
gene specific primers in a quantitative real-time RT-PCR procedure with SYBR 
green (SA Biosciences, Valencia, CA). All primers were synthesized by 
Integrated DNA Technologies, Inc. (IDT; San Diego, CA).   
RT-PCR Primer Sequences: 
SDF-1F : GTCAGCCTGAGCTACAGATGC (Boudot et al. 2011) 











Coimmunoprecipitation (CoIP) Assay 
Cells were plated in 10 cm tissue culture plates and harvested 48 hours later. 
Cells were lysed in 0.5% NP-40 lysis buffer and sonicated three times for 30 
seconds. Cell lysates were immunoprecipitated with -ER, -c-fos, -c-jun or 
normal rabbit IgG (Santa Cruz Biotechnology) for 2 hours followed by incubation 
with either protein A or G agarose beads for 1 hour. Protein complexes were 
separated with SDS-PAGE followed by Western blot analysis with ER, c-jun, c-
fos, and normal rabbit IgG antibodies. 
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Chromatin Immunoprecipitation (ChIP) Assay 
Cells were plated in 10cm plates and harvested by fixation with formaldehyde.  
Cells were lysed and sonicated in lysis buffer to fragment the chromatin into 1-2 
kb fragments.  Chromatin mixtures were immunoprecipitated with antibodies 
specific for ER, c-fos, and c-jun (Santa Cruz Biotechnology). Antibody 
complexes were purified using protein A agarose beads (Pierce, Rockford, IL). 
The complexes were reverse-cross-linked to release the chromatin fragments by 
incubation at 65oC for 4-6 hours. DNA fragments were purified using QIAQuick 
columns (Qiagen, Germantown, MD).  Occupancy at a specific promoter was 
determined with PCR using promoter specific primers.  PCR products were 
detected with agarose gel electrophoresis and quantitated using Quantity One ® 
(Biorad, Hercules, CA).  
ChIP Primer Sequences: 
SDF1-ChIPF:  CACCATTGAGAGGTCGGAAG (Boudot et al. 2011) 
SDF1-ChIPR: AATGAGACCCGTCTTTGCAG (Boudot et al. 2011) 
cyclin D1-ChIPF: CATTCAGAGGTGTGTTTCTCCC 
cyclin D1-ChIPR: CTCAGCGACTGCATCTTCTTTC 
c-myc-ChIP F:GACACATCTCAGGGCTAAACAG 






For the re-ChIP assay, protein A-antibody complexes resulting from the first ChIP 
assay were extracted twice after incubation with 100l of 10mM DTT for 20 















































Figure 1: Chronic cadmium exposure induces more aggressive cancer phenotypes: cell growth, migration and invasion. (A) MCF7-Cd
cells (black bars) and parental MCF-7 cells (white bars) were plated in 6 well plates under hormone-deprived conditions and cell growth was moni-
tored 2, 4, and 6 days after plating by counting in triplicate. Experimental results are averages of three independent experiments (P<0.01). (B) A
scratch wound assay was used to assess cell migration ability. MCF-7 and MCF7-Cd cells were plated in 6-well plates and allowed to reach 70-
80% confluence. A scratch was created using a p-200 pipette tip and a digital image was captured on Day 0. Cells were then allowed to grow and
migrate for 3 days and images of the wound were captured 3 days later. (C) Modified Boyden chamber assays were performed to measure the
migration abilities of the cells. MCF7 (white bars) and MCF7-Cd (black bars) cells were seeded into upper chambers and cells were allowed to
migrate to lower chamber for 15-18 hours. Data is representative of 3 independent experiments performed in triplicate (P< 0.01). (D) An invasion
assay was performed by seeding either MCF7 (white bars) or MCF7-Cd (black bars) cells in the upper chambers. Cells were allowed to invade
through matrigel-coated membranes for 18-24 hours.Data is an average of 3 independent experiments done in triplicate (P<0.01).
ChIP Buffer (20 mM Tris- HCl,  pH 8.1,  2 mM EDTA, 150 mM NaCl, and 0.1% 
Triton X-100). The chromatin mixture was re-ChIPed with the second antibody: 
-ER, -c-jun, -c-fos or normal rabbit IgG, (Santa Cruz Biotechnology). 
Antibody complexes were purified using protein A beads, and the complexes 
were reverse-cross-linked to release the chromatin fragments after an incubation 
at 65oC for 4-6 hours. The DNA was purified with QIAQuick and analyzed as 
previously described.   
 
Luciferase Reporter Assay 
The reporter gene assay was performed by sequentially transfecting MCF7 cells 
with siRNA targeting ER (Santa Cruz Biotechnology) followed by the SDF1 
promoter-Luc reporter plasmid.  Five hours after siRNA transfection, the second 
transfection with the SDF-1 Luc reporter plasmid along with the pRL-SV40 
Renilla luciferase plasmid (Promega) was accomplished using Fugene HD 
(Promega) according to the manufacturer’s protocol. The medium was changed 
to DMEM media containing 10% FBS and penicillin and streptomycin, and cells 
were harvested 48 hours post-transfection and analyzed using a dual luciferase 
assay kit (Promega). All reporter gene assays were performed in quadruplicate, 
with the entire experiment repeated at least three times. SDF-1-Luc was 
purchased from Genecopoeia (Rockville, MD). 
 
2.3 Results  
 We previously found that acute cadmium exposures increase growth rates 
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of three ERα positive breast cancer cell lines— MCF7, T-47D and ZR-75-1— and 
increases the expression of genes associated with growth (Siewit et al. 2010).  
The observation that acute cadmium exposure stimulates breast cancer cell 
proliferation led us to question the effects of chronic cadmium exposure on 
breast cancer progression. To understand how chronic cadmium exposure 
affects the progression of ER-positive breast cancer, a cell line chronically 
exposed to cadmium was developed by exposing cells to low concentrations of 
cadmium (10-7 M) for over six months. Since cancer progression often results in 
the acquisition of more aggressive phenotypes, including an increased growth 
rate (Hanahan and Weinberg 2000), the effects of prolonged cadmium exposure 
on cancer cell growth was assessed.  The growth properties of cells chronically 
exposed to cadmium (MCF7-Cd) were analyzed in the presence or absence of 
cadmium and compared to parental MCF7 cells.  Approximately 2.5x104 cells 
were plated in 6-well plates under hormone-deprived conditions and treated with 
10-7 M cadmium chloride (CdCl2) or mock treated with phosphate buffered saline 
(PBS).  Cell growth was monitored 2, 4 and 6 days after treatment.  The MCF7-
Cd cells displayed a significantly faster growth rate than the parental MCF7 cells 
in both the presence and absence of cadmium, suggesting that cells exposed to 
prolonged periods of cadmium have accelerated growth (Fig. 1A).  
 In addition to increased growth rates, one of the characteristics that cancer 
cells acquire as they become more malignant is the ability to metastasize 
(Hanahan and Weinberg 2000). This is characterized by an increased ability to 
migrate and invade the extracellular matrix. Therefore, the migration ability of 
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cells chronically exposed to cadmium was analyzed and compared to parental 
MCF7 cells by using a scratch wound assay (Fig. 1B). Again, cells were plated in 
a 6-well plate, and when cells reached 70% confluence, a wound was created 
using a p200 pipette tip.  Cells were rinsed with PBS and migration was observed 
3 days later. The data suggest that MCF7-Cd cells display a greater migration 
ability than the parental MCF7 cells (Fig. 1B). 
 To confirm the qualitative observations in Figure 1B, a modified Boyden 
Chamber assay was used to quantify the effects of chronic cadmium exposure 
on breast cancer cell migration (Fig. 1C).  In this assay, 5x104 cells of each cell 
type (MCF7 or MCF7-Cd) were plated in the upper chamber and allowed to 
migrate for 16 hours through an 8µM polycarbonate membrane.  Cells that have 
the ability to migrate were able to attach to the underside of the membrane 
whereas non-migratory cells stayed in the upper chamber. Cells on the underside 
of the membrane were fixed and stained with crystal violet, and a microscope 
was used to determine the number of cells migrated in each well. The results 
suggest that cells chronically exposed to cadmium display an increased ability to 
migrate (31 vs. 54, p < 0.05, Fig. 1C). The invasive ability of the MCF7-Cd cells 
was also investigated using a similar assay, but the membranes in the chambers 
were coated with matrigel in order to mimic the extracellular matrix (Fig. 1D). 
Again, 5x104 cells (MCF7 or MCF7-Cd) were added to the upper chamber, and 
cells with the ability to invade were able to digest the matrigel and attach to the 
underside of the chamber.  Cells were allowed to invade for 18 hours and then 
counted as in the migration assay.  Consistent with the results from the migration 
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assay, MCF7-Cd cells also displayed a greater ability to digest the matrigel and 
invade (48 vs 94, p < 0.05). 
 To understand the molecular alterations that occur in the cells exposed for 
prolonged periods to cadmium, clonal cell lines (MCF7-Cd2 to Cd12) were 
derived from MCF7-Cd cells, and differentially expressed genes were analyzed 
using both a metastasis-specific PCR array (Superarray RT-Profiler) and 
microarray. Both array studies identified SDF-1, also known as CXCL12, as 
being up-regulated in a majority of the cadmium-adapted cells. Further 
verification using semi-quantitative RT-PCR demonstrated that about 70% of the 
cadmium adapted cell lines expressed higher levels of SDF-1 (Fig. 2A), with Cd7 
and Cd12 expressing the highest levels.  The levels of SDF-1 protein present in 
the Cd7 and Cd12 cells and secreted into the media were also examined using 
Western blot analysis and ELISA, respectively.  Consistent with the gene 
expression data, levels of SDF-1 in both the protein lysates and in the media 
were elevated, as shown in Figures 2B and C. 
 Interestingly, SDF-1 has been shown to be an estrogen receptor (ERα) 
regulated gene (Hall and Korach 2003).  Since cadmium functions as a 
metalloestrogen, we questioned whether cadmium could induce the expression 
of SDF-1. To determine if the expression of SDF-1 is regulated by acute 
cadmium exposure, parental MCF7 cells were treated with either 10-6 M CdCl2 or 
10-7 M 17-estradiol. The results in figure 3 indicate that both acute cadmium and 
estrogen can increase SDF-1 expression by 6 and 12 fold, respectively (Fig. 3 A-
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Figure 2: Chronic cadmium exposed cells express and secrete higher levels of SDF-1. (A)
MCF7 and MCF7-Cd clonal derivatives (Cd-2, -4, -6, -7, -8, -11 and -12) were plated in 6 well
plates and total RNA was isolated for gene expression analysis using semi-quantitative PCR.
GAPDH was used as a loading control. (B) SDF-1 protein expression in MCF7, Cd7, and Cd12
cells was analyzed with Western blot analysis. Actin was used as a loading control. (C) Condi-
tioned media was collected in the same experiments shown in B after 24 hours, and the levels of
SDF-1 were measured with an enzyme-linked immunosorbent assay (ELISA). Data is represen-
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Figure 3: SDF-1 is induced by acute cadmium and estrogen exposure. MCF7 cells were
hormone deprived and treated with either 10-7 M E2 (white bars) or 10-6 M CdCl2 (black bars).
Ce l ls were harves ted fo r gene express ion ana lys is us ing (A) quant i ta t ive and
(B) semi-quantitative RT-PCR. Quantitative PCR data is presented as relative SDF-1 fold
increases.
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hours, whereas cadmium-induced SDF-1 expression peaked after 8 hours of 
exposure.  Although, cadmium induction was not as robust as 17-estradiol 
induction, these results clearly demonstrate that cadmium has the ability to 
stimulate SDF-1 expression within hours of exposure.  
Given that SDF-1 is an ER-target gene, SDF-1 expression was further 
analyzed in the Cd-cell lines to see if it was dependent on ER by depleting 
endogenous levels of ER (Fig. 4). To mediate ER silencing (Ei), siRNA was 
transfected into parental MCF7, MCF7-Cd4,-Cd7 and -Cd12 cells, and the effects 
of decreased ER levels on SDF-1 expression were examined.  Cells transfected 
with scrambled siRNA were used as controls (Ci). At 48 hours after transfection, 
cells were collected for both protein and gene expression analyses using 
Western blot and semi-quantitative RT-PCR, respectively (Fig. 4A-B). Gene 
expression analysis was also confirmed by quantitative RT-PCR (qRT-PCR) (Fig. 
4C). As expected, the successful depletion of ER by siRNA resulted in lower 
levels of SDF-1 in parental MCF7 cells. Interestingly, a similar effect was 
observed in cells chronically exposed to cadmium, suggesting that SDF-1 
expression in the cadmium-adapted cells is also dependent on ER.  To 
determine if ER plays a direct role in regulating the transcription of SDF-1, a 
luciferase reporter assay was used in the presence and absence of ERα (Fig. 
4E).  MCF7, Cd7 and Cd12 cells were transfected with either a control siRNA 
(Ci) or one that targets ER (Ei). The depletion of ERas shown by the Western 
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Figure 4: SDF-1 expression in cells chronically exposed to cadmium is dependent on ERα. MCF7, Cd4, Cd7 and Cd12 cells were plat-
ed in 6-well plates and transfected with either si-ERα (Ei) or si-control (Ci), and collected 48 hours after treatment for protein and gene
expression analyses using (A) Western blot and (B) RT-PCR, respectively. Changes in gene expression were also measured using (C) quan-
titative RT-PCR, and fold knockdown was expressed as CtEi/ CtCi. Fold knockdown of ERα and SDF-1 are represented in white and black,
respectively. Data is representative of at least three independent experiments done in triplicate. GAPDH was used as a control. MCF7, Cd7
and Cd12 were also transfected with siRNA targeting ERα and the transactivation of the SDF-1 promoter measured using a luciferase report-
er assay. Following transfection, cells were collected for (D) Western blot analysis and (E) reporter gene assay. Data represents at least
three independent experiments done in quadruplicate. Actin was used as a loading control for the Western blot.
cell lines (Fig. 4E), further establishing the role of ER in regulating the 
expression of SDF-1.  
 Although SDF-1 is an ER-regulated gene, it is unclear whether ER 
regulates SDF-1 alone or in collaboration with other transcription factors.  To 
determine if ERinteracts with other transcription factors, a co-
immunoprecipitation experiment was used to identify potential transcription 
factors that may interact with ER in cells chronically exposed to cadmium (Fig. 
5).  Cells were grown for 48 hours, and cell lysates were immunoprecipitated with 
α-ERα antibodies. The presence of specific transcription factors in the 
immunoprecipitated complexes was determined with Western blot analysis. 
Results in figure 5A indicate that a greater fraction of c-fos and c-jun co-
precipitated with ER in the Cd7 and Cd12 cells when compared to the parental 
MCF7 (M) cells, whereas similar levels of Sp-1 and -catenin— two transcription 
factors known to interact with ER— were found in both parental MCF7 cells and 
cells chronically exposed to cadmium (Fig. 5A).  Changes in the interaction of 
ER with c-jun and c-fos were further confirmed by reciprocal co-
immunoprecipitation with antibodies against c-jun and c-fos (Fig. 5B).  
 Despite the observation that ER co-precipitates with both c-jun and c-fos, 
it is unclear whether these AP-1 transcription factors are directly involved in the 
regulation of SDF-1. To understand the role of c-jun and c-fos in mediating the 
expression of SDF-1, the expression of SDF-1 cells was analyzed following 
siRNA-mediated silencing of c-jun and c-fos (Fig. 5C). MCF7, Cd7 and Cd12 








































Figure 5: Prolonged exposure to cadmium enhances the interactions of ERα with c-jun
and c-fos. (A) MCF7, Cd7 and Cd12 cell lysates were immunoprecipitated with either α-ERα or
normal rabbit IgG. Proteins interacting with ERα were analyzed with Western blot analysis. (B)
Reverse co-IP was performed with α-c-Jun, α-c-Fos, or normal rabbit IgG. (C) MCF7, Cd7 and
Cd12 were plated in 6-well plates and transfected with siRNA targeting either c-jun (Ji), c-fos (Fi)
or a scramble siRNA control (Ci) and collected 48 hours later for protein analysis.
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were harvested 48 hours later for Western blot analysis (Fig. 5C).  While lower 
levels of c-jun and c-fos resulted in a significant reduction of SDF-1 expression, 
these lower levels of c-jun and c-fos apparently led to decreased levels of ER, 
complicating the determination of whether c-jun and c-fos directly regulate SDF-1 
expression. 
 Since the regulatory region of SDF-1 consists of only one full ERE site 
located 234 bp upstream of the promoter, five half ERE sites located within the 
proximal promoter, and multiple AP-1 and Sp-1 sites on the promoter (Boudot et 
al 2011), it is probable that ER may interact with other transcription factors to 
regulate SDF-1 expression. Therefore, a chromatin immunoprecipitation (ChIP) 
assay was used to determine whether a greater fraction of c-jun and c-fos is 
recruited to the SDF-1 promoter in cells chronically exposed to cadmium. Cells 
were plated for 48 hours and harvested for ChIP analysis.  The recruitment of 
ERα, c-jun and c-fos was analyzed by PCR. Results in Figures 6A and B indicate 
that cells chronically exposed to cadmium (Cd7 and Cd12) had higher levels of 
ERα recruited to the SDF-1 promoter in comparison to parental MCF7 (M) cells 
(27% and 47% vs. 15%, respectively). Similarly, the occupancy of c-jun and c-fos 
on the SDF-1 promoter were significantly elevated in Cd7 and Cd12 cells when 
compared to parental MCF7 cells, with c-jun showing at least a 2-fold increase 
(Fig. 6A-B).  The occupancy of all three transcription factors (ER, c-jun, and c-
fos) was also found elevated in the cyclin D1 and c-myc promoters of cells 
chronically exposed to cadmium (Fig. 6A-B).  In contrast, Sp-1 was only found 
elevated on the c-myc promoter of cells chronically exposed to cadmium (Cd7 
44
c-Fos IP c-Jun IP Sp-1 IPInput ERα IP












































































M 7 12 M 7 12 M 7 12
ERα ERα/c-jun ERα/c-jun/c-fos
Figure 6: ERα, c-fos and c-jun are recruited to SDF-1 promoter. (A) MCF-7, Cd7 and Cd12
cells were harvested for chromatin immunoprecititation (ChIP) analysis. ChIP analysis was
done with α-ERα, α-c-Fos, α-c-Jun, and α-Sp1, and recruitment of proteins to the SDF-1, cyclin
D1 and c-myc promoters was determined using promoter speci f ic pr imers and
semi-quantitative PCR. (B) Band intensities of PCR products for SDF-1, cycD, and c-myc were
quantified and normalized to input using Quantity One (Bio-Rad) (P<0.001). (C) In the ChIP
re-ChIP assay, DNA/protein complexes from the first ChIP assay were extracted and re-
ChIPed with a second antibody. The occupancy of ERα/c-jun or c-Jun/ERα complexes on the
SDF-1 promoter was analyzed as in B (P<0.001). (D) To confirm the presence of c-fos in the
ERα/c-jun complex on SDF-1, reChIPed DNA  containing ERα/c-jun complexes were immuno-
precipitated with α-c-fos antibody, and the resulting DNA fragments were analyzed as in B 
(P<0.001).
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and 12); no significant difference in Sp-1 levels was observed on the SDF-1 and 
cyclin D1 promoters among the different cell lines (Fig. 6A). 
While the results from the ChIP assay strongly support the notion that 
ER, c-jun and c-fos all regulate SDF-1 expression, it is unclear whether these 
transcription factors work independently or together as one regulatory complex. 
To fully understand the components of the transcription complex regulating SDF-
1 expression, a ChIP re-ChIP assay was performed. Following the first ChIP 
assay with either ER or rabbit IgG as a control, the DNA-protein complexes 
were extracted and re-ChIPed with a second antibody (c-jun, or rabbit IgG). Data 
from both forward and reverse ChIP re-ChIP assays display higher levels of 
ER/c-jun complex bound to the SDF-1 promoter in Cd7 and Cd12 cells when 
compared to parental MCF-7 cells (Fig. 6C). Since previous studies have 
suggested that ER and c-fos do not interact directly (Teyssier et al. 2001), we 
evaluated the presence of c-fos in the ER/c-jun complex using a triple-ChIP 
assay (three sequential chromatin IPs), in which the re-ChIPed DNA containing 
ER/c-jun complexes was immunoprecipitated with a third antibody (c-fos or 
rabbit IgG) to verify the presence of c-fos in the complex. Results in Figure 6D 
not only confirm the occupancy of ER/c-jun complex on the SDF-1 promoter, 
but also demonstrate that c-fos is involved in transcriptional regulation of SDF-1 
in both parental and cadmium-adapted cell lines.   
 
2.4 Discussion  
Often referred to as an endocrine disruptor, cadmium is an environmental 
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contaminant that has been shown to have the ability to bind to the estrogen 
receptor and alter the expression of various estrogen receptor target genes 
(Martin et al. 2003, Garcia-Morales et al. 1994, Siewit et al. 2010, Yu et al. 2010). 
While epidemiological and animal studies (Martin et al. 2003, Johnson et al. 
2003, Hofer et al. 2009, Alonso-Gonzalez et al. 2007, Ali et al. 2010, Waalkes et 
al. 1999, Gunn et al. 1964, Poirier et al. 1983) have implicated cadmium as a 
carcinogen, there is no direct evidence suggesting cadmium promotes breast 
cancer in humans.  Despite this, the International Agency for Research on 
Cancer (IARC) has classified cadmium as a potential human carcinogen. 
Although multiple studies— including work from this lab— have demonstrated 
that acute cadmium exposures can stimulate breast cancer cell growth and can 
activate the estrogen receptor to mediate the expression of genes associated 
with cell growth (Stoica et al. 2000, Martin et al. 2003, Garcia-Morales et al. 
1994, Choe et al. 2003, Liu et al. 2008, Brama et al. 2007), less is known about 
how chronic exposures of cadmium may contribute to the development and 
progression of breast cancer. Studies on prostate cancer and sarcomas have 
indicated that chronic exposures to cadmium can be associated with more 
malignant tumors (Waalkes et al. 2000, Achanzar et al. 2001, Haga et al. 1996). 
Additionally, significantly higher levels of cadmium have been found in breast 
tumor tissues in comparison to non-tumor tissues (Antila et al. 1996, Strumylaite 
et al. 2011, Strumylaite et al. 2008, Romanowicz et al. 2011, Ionescu et al. 
2006). The chronic effects of cadmium on the progression of breast cancer and 
the molecular alterations induced by cadmium have never before been fully 
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elucidated.   
Results from this study confirm that chronic cadmium exposure does 
promote the development of more aggressive cancer characteristics, including 
increased cell growth and an increased ability to migrate and invade (Fig. 1). To 
understand the impact of chronic cadmium exposures at the molecular level, 
clonal cell lines were developed from the original MCF7-Cd cell line (MCF7-Cd-2 
to 12), and it was found that SDF-1, one of the genes identified in microarray 
expression analysis, was elevated in more than 70% of the cadmium-adapted 
cell lines (Fig. 2A).  In addition to expressing higher levels of SDF-1 at the mRNA 
level, cells chronically exposed to cadmium (MCF7-Cd7 and Cd12) also 
expressed and secreted more SDF-1 protein into the media (Fig. 2B-C), 
consistent with its function as a chemokine, a factor that promotes cell migration 
and metastasis (Mukherjee et al. 2013).  
Interestingly, past studies have also shown SDF-1 to be regulated by ER 
(Hall and Korach 2003, Boudot et al. 2011, Zhu et al. 2006). Consistent with 
these findings, SDF-1 mRNA levels were indeed shown to increase within hours 
of the cells being treated with 17-estradiol (Fig. 3A-B).  Strikingly, our results 
demonstrate that the metalloestrogen cadmium can also stimulate SDF-1 gene 
expression, but to a lesser extent than 17-estradiol (6 fold vs. 12 fold, Fig. 3).  
To establish a link between chronic cadmium-induced SDF-1 expression and 
ER, siRNA was used to reduce intracellular levels of ER in parental MCF7, 
MCF7-Cd4, -Cd7, and -Cd12 cells. Results showed that suppressing ERα 
expression subsequently inhibited the expression of SDF-1 in both MCF7 cells 
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and in cells chronically exposed to cadmium, suggesting that elevated SDF-1 
expression is in part dependent on ER (Fig. 4).  In order to determine whether 
ER regulates the transcription of the SDF-1 gene, a luciferase reporter assay 
was used with SDF-1-luc and co-transfected siRNAs to silence ER.  Results in 
Figure 4E suggest that depletion of ER, as indicated by Western blot analysis 
(Fig. 4D), significantly reduces transcriptional activation of the SDF-1 promoter.  
Similarly, silencing ER in cadmium-adapted and parental MCF-7 cells also 
decreased other ER target genesspecifically cyclin D1 and c-myc (Fig. 4). This 
further indicates that the estrogen receptor signaling pathway is intact and may 
have a heightened response in cells chronically exposed to cadmium.  
To determine if chronic cadmium exposure enhances the interaction of 
ER with other transcription factors, co-immunoprecipitation experiments were 
performed. Results in Figure 5A show that a greater fraction of c-jun and c-fos 
co-precipitated with ER in the cadmium-exposed cells. These interactions were 
confirmed by reciprocal co-immunoprecipitation (co-IP) with either c-jun or c-fos 
(Fig. 5B). While the interaction of ER with c-jun is well-documented (Strumylaite 
et al. 2008, Romanowicz et al. 2011, Ionescu et al. 2006, Hanahan and 
Weinberg 2000), the direct interaction between ER and c-fos has not been 
documented.  More specifically, a study by Teyssier et al. demonstrated that ER 
binds directly to c-jun, but not to c-fos, in pull-down assays (Teyssier et al. 2001).  
Although our co-IP results show an ER/c-fos interaction, it is important to note 
that this interaction may be mediated indirectly by c-jun, especially since c-jun 
and c-fos often function as heterodimers (Bjornstrom et al. 2005). Consistent with 
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the results presented in this study, previous studies have demonstrated that both 
cadmium and arsenic can increase the interactions of ER with c-jun under acute 
exposures (Siewit et al. 2010, Qi et al. 2004). 
Though promising, the increased interactions between ER, c-jun and c-
fos do not prove that these complexes are directly involved in regulating the 
expression of SDF-1 in cells chronically exposed to cadmium.  We attempted to 
show this via siRNA-mediated silencing of c-jun and c-fos, which did result in a 
reduction of SDF-1. Unfortunately, the data could not clearly demonstrate 
whether the decrease in SDF-1 was due solely to c-jun or c-fos since the down 
regulation of c-jun and c-fos also decreased ER levels, which is already known 
to affect SDF-1 levels (Fig. 5C).  
To confirm the roles of ER, c-jun and c-fos in the transcriptional 
regulation of SDF-1 in cells chronically exposed to cadmium, chromatin 
immunoprecipiation (ChIP) assays were then used to determine the occupancy 
status of each transcription factor on the SDF-1 promoter.  In line with previous 
reports by Zhu et al. and Boudot et al., our results demonstrate that ER is 
recruited to the SDF-1 promoter and furthermore, the promoter occupancy by 
ERα is elevated in cells chronically exposed to cadmium (Fig. 6A-B) (Boudot et 
al. 2011, Zhu et al. 2006). A greater fraction of c-jun and c-fos were also found 
on the SDF-1, cyclin D1, and c-myc promoters after chronic cadmium exposure. 
In contrast, the levels of transcription factor Sp-1 were only elevated on the c-
myc promoter. 
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Whether ER regulates the expression of SDF-1 by binding to classical 
ERE sites or via interactions with other transcription factors was uncertain.  
However, based on the occupancy patterns of c-jun and c-fos on the SDF-1 
promoter, it seemed conceivable that SDF-1 is regulated in a similar manner as 
cyclin D1 and c-myc— both of which are regulated by the interaction of ERα with 
c-jun/c-fos heterodimers (Klein et al. 2008, Cicatiello et al. 2004, Castro-Rivera et 
al. 2001, Wang et al. 2011, Shang et al. 2000). Since the interaction between 
ER and c-fos is likely mediated indirectly by c-jun (Bjornstrom et al. 2005), 
further studies were carried out using both ChIP re-ChIP and triple-ChIP assays 
to determine if ER regulates SDF-1 via interactions with c-jun/c-fos heterodimer. 
Data from both forward and reverse ChIP re-ChIP assays suggested that cells 
chronically exposed to cadmium (Cd7 and Cd12) exhibited higher levels of 
ER/c-jun complexes on the SDF-1 promoter (Fig. 6C). The increase in ER/c-
jun interactions further emphasizes the importance of ER and c-jun in regulating 
SDF-1 expression, especially in cells chronically exposed to cadmium.  
Consistent with these results, c-jun has been shown to regulate SDF-1 
expression in other cell types (Florin et al. 2004, Florin et al. 2005).  These new 
results also mirrored those from our previous study, which had demonstrated that 
the ER/c-jun interaction was important in modulating the expression of genes in 
response to acute cadmium exposure (Siewit et al. 2010). Interestingly, the 
ER/c-jun interaction has also been shown to be important in cells exposed to 
arsenic stress (Qi et al. 2004), suggesting this may serve as a common metal-
response mechanism. 
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In summary, the results from this study demonstrate for the first time that 
chronic cadmium exposure promotes the acquisition of more aggressive cancer 
phenotypes (e.g. growth, migration and invasion) by stimulating the expression of 
SDF-1, and altering the molecular interactions between ER, c-jun and c-fos. 
Additionally, the data in this study suggest that the molecular dynamics of cells 
chronically exposed to cadmium are significantly different from cells that are not 
exposed to cadmium.   We speculate that the molecular interactions of ERα with 
other transcription factors, including other members of the AP-1 family and 
members of E2F and NFkB families are also affected by chronic cadmium 
exposure, and likely in a promoter-specific manner (Marino et al. 2006, Klinge et 
al. 2004). Since estrogen receptor is known interact with many coactivators and 
corepressors (Shang et al. 2000, Florin et al. 2004, Florin et al. 2005, Marino et 
al. 2006, Klinge et al. 2004), it would also be interesting to determine how chronic 
cadmium exposure may alter the molecular interactions between ER and its 
coregulators in future studies.  The results presented in this study offer molecular 
insights into how mammary tumors containing significant levels of cadmium can 
become more aggressive and underscore the importance of studying the 
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CHRONIC CADMIUM EXPOSURE DISRUPTS CELL-TO-CELL ADHESIONS 
BY DOWN-REGULATING E-CADHERIN 
 
3.1 Introduction 
As stated in the previous chapter, cells exposed to cadmium for prolonged 
periods of t ime have been shown to di splay more aggressive cancer phenot ypes 
that include an increased abilit y to grow i n an anchorage-independent fashion 
and the capacity to invade surrounding ti ssue (Benbrahim-Tallaa et al. 2009, 
Achanzar et al. 2001). Invasion and subsequent metastasis require the 
detachment of cells from the pri mary tumor site.  One way this can be achieved 
is through loss of cell adhesion mole cules such as E-cadherin and catenin. E-
cadherin is  a transmembrane glycoprotein which play s a key role in hemophilic  
Ca2+-dependent cell-to-ce ll adhesion (Pearson and Proz ialeck 2001). 
Specifically, E-cadherin associates with actin microfilaments via catenin, a key 
protein coordinating cell-to -cell adhesions. Studies have shown  that cadmium  
may replace calcium in the E-cadherin ce ll-to-cell junctions, thus disrupting t he 
cadherin/catenin complex (Pr ozialeck a nd Niewenhuis 1991, Prozialeck and 
Lamar 1997), but such studies  have not  demonstrated a link between this  
cadmium-induced disruption and the development of  invasive/metastatic  
phenotypes in breast cancer. 
This study aims to understand how chronic cadmium exposure contributes 
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between E-cadherin and catenin. We provide several lines of evidence that 
suggest that prolonged cadmium exposure disrupts the cell-to-cell adhesion 
molecules E-cadherin and catenin. Our results demonstrate that MCF7 breast 
cancer cells chronically exposed to cadmium have decreased E-cadherin 
expression and subsequently a diminished number of E-cadherin/β-catenin 
complexes. In short, these results suggest that chronic exposure to heavy metals 
like cadmium disrupts inter- and intracellular adhesion protein complexes to 
facilitate breast cancer progression by mediating molecular changes that alter the 
cancer cells’ ability to migrate and invade (Chapter 2). 
 
3.2 Materials and Methods 
Cell Culture 
MCF7 cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). MCF7-Cd was developed by exposing parental MCF7 cells to 
10-7 M CdCl2 for over 6 months, and clonal cell lines Cd7 and Cd12 were derived 
from this line. Parental MCF7 and MCF7-Cd7 and -Cd12 were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal 
Bovine Serum (FBS; Hyclone, Logan, UT) and antibiotics. Both cell lines were 
subcultured every 3-4 days. 
 
Western Blot  
Cells were lysed in 1% SDS-HEPES buffer and total protein concentration was 
normalized using the Bio-Rad Dc Protein Assay kit (Bio-Rad, Hercules, CA). 
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Total protein was separated via SDS-polyacrylamide gel electrophoresis and 
transferred to polyvinyl difluoride (PVDF) membranes (Millipore, Billerica, MA). 
Protein expression was monitored using protein-specific rabbit polyclonal 
antibodies: -CDH-1 (Santa Cruz Biotechnology, Santa Cruz, CA), catenin 
(Santa Cruz Biotechnology, Santa Cruz, CA), and -GAPDH (Cell Signaling 
Technology, Danvers, MA. 
 
Reverse Transcriptase Polymerase Chain Reaction (RT- PCR) 
Total RNA was isolated from normal MCF7, MCF7-Cd4, Cd7, and Cd12 using 
TRI-Reagent (Zymo Research Corporation, Irvine, CA) and columns from the 
Direct-zol RNA MiniPrep kit (Zymo Research) according to manufacturer’s 
protocol. Three micrograms (g) of total RNA were used for the reverse 
transcription reaction with oligo-dT18 primers and Moloney Murine Leukemia Virus 
Reverse Transcriptase (M-MLV RT, Promega, Madison, WI). Gene expression 
was monitored using semi-quantitative PCR for 28 cycles. PCR products were 
separated by agarose gel electrophoresis and visualized using the Chemi-Doc 
gel documentation system (Bio-Rad, Hercules, CA). Gene expression was 
quantified by quantitative real-time RT-PCR using the SYBR Green real-time 
PCR master mix (SA Biosciences, Valencia, CA). All primers were synthesized 
by Integrated DNA Technologies, Inc. (IDT; San Diego, CA). Primers used and 
their sequences are as follows: 








Coimmunoprecipitation (CoIP) Assay 
MCF7, MCF7-Cd7 and -Cd12 were plated in 10cm plates and harvested 48 
hours later. Cells were lysed in 0.5% NP-40 lysis buffer and sonicated three-
times for 30 seconds. Total protein cell lysates were treated with anti-E-cadherin 
antibody (Santa Cruz Biotechnology) for 2 hours and then incubated with either 
protein A or G agarose beads for 1 hour. Protein complexes were separated by 
SDS-PAGE followed by Western blot analysis.  Membranes were probed for E-
cadherin (Santa Cruz Biotechnology), -catenin (Santa Cruz Biotechnology) or 
normal rabbit IgG (Santa Cruz Biotechnology).  
 
Immunofluorescence Microscopy 
MCF-7, MCF7-Cd7 and -Cd12 were plated on 6-well plates containing sterile 
cover slips. Cells were fixed 24 hours later in 10% formalin. Protein expression 
was analyzed using monoclonal antibodies to -catenin (Santa Cruz 
Biotechnology), polyclonal antibodies to E-cadherin (Cell Signaling Technology), 
or polyclonal antibodies to active -catenin (Cell Signaling Technology). 
Secondary antibodies conjugated to Alexa-488 (green) and Alexa-647 (red) 
(Molecular Probes, Life Technologies, Grand Island, NY) were used to detect 
protein expression and images were visualized using a fluorescent microscope 




Previous data from our lab suggest that MCF7 cells chronically exposed to 
cadmium (MCF7-Cd) display increased metastatic phenotypes—including 
changes in migration, cell adhesion and invasion—all of which are characteristics 
of cancer progression.  Other studies have also implicated E-cadherin in many of 
these processes. To understand how chronic cadmium exposure affects the 
expression of E-cadherin, clonal cell lines (MCF7-Cd7, Cd12) derived from cells 
chronically exposed to cadmium were used for expression analysis and 
compared to those of parental MCF7 cells.  Gene and protein expression levels 
were analyzed by semi-quantitative RT-PCR and Western blot, respectively (Fig. 
1 A-B). Results shown in Figure 1A suggest that cells chronically exposed to 
cadmium (Cd7 and Cd12) express similar levels of E-cadherin at the transcription 
level as the parental MCF7 cells.  There is also no significant difference in β-
catenin gene expression among the cadmium-adapted and parental MCF7 cells.  
However, cells chronically exposed to cadmium did express lower levels of E-
cadherin at the protein level (Figure 1B). This effect was not uniformly observed 
with -catenin, as one cadmium-exposed clone demonstrated a significant 
decrease in expression (Cd12) while another showed no appreciable change in 
-catenin expression (Cd7) when compared to the parent cell line.  To determine 
if the cadmium-induced decrease of E-cadherin is specific to only chronic 
exposures, we treated parental MCF7 cells with 10-6 M cadmium chloride (CdCl2) 
and compared it to cells treated with 10-7 M estrogen under acute conditions.  
Cells were then harvested 0, 1, 2, 4, 8, 12 and 24 hours after treatment, and 
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Figure 1: Cells chronically exposed to cadmium express lower protein levels of
E-cadherin. (A) MCF7, MCF7-Cd7 and -Cd12 were plated in 6 well plates and total RNA was
isolated for gene expression analysis using semi-quantitative PCR. (B) Protein expression in
MCF7, Cd7, and Cd12 cells was analyzed by Western blot analysis.
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protein expression was analyzed using Western blot analysis. Results in Figure 2 
show that both cadmium and estrogen are able to promote down-regulation of E-
cadherin protein expression under acute conditions. In contrast, the expression 
of total -catenin was elevated in response to both acute cadmium and estrogen 
treatment. Other than the membrane-localized form of -catenin that normally 
interacts with E-cadherin to mediate cell-cell interaction, -catenin also exists in a 
dephosphorylated or active form that functions as a transcription factor to 
regulate gene expression in the nucleus.  We also evaluated the levels of active 
-catenin and found that— similar to total -catenin levels— the active form was 
also increased in response to cadmium and estrogen (Fig. 2).  
Since E-cadherin and -catenin often function in a complex to mediate 
cell-cell adhesion, we question whether the cadmium-induced decrease of E-
cadherin may alter this interaction.  To determine if the interaction between E-
cadherin and -catenin are disrupted in cells chronically exposed to cadmium, 
cells were collected for co-immunoprecipitation assays.  Total cell lysates of both 
cadmium-adapted (Cd7 and Cd12) and parental MCF7 cells were 
immunoprecipitated with antibodies against E-cadherin. Results in Figure 3 show 
a decrease of -catenin protein complexed to E-cadherin in cells chronically 
exposed to cadmium (7 and 12) in comparison to the parental MCF7 cells (M).  
To verify that fewer E-cadherin/-catenin complexes exist within cells 
chronically exposed to cadmium, we also examined the expression of this protein 
complex using immunofluorescence microscopy. Results in Figure 4 show that 
both parental (MCF7) and cadmium-adapted cells (Cd7 and Cd12) express E-
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Figure 2: Acute cadmium and estrogen exposures promote the down-regulation of
E-cadherin. MCF7 cells were plated in 6-well plates and treated with 10-6 M CdCl2 or 10
-7 M
E2. Cells were harvested 0, 1, 2, 4, 8, 12, and 24 hours after treatment for protein expression









Figure 3: Chronic cadmium exposure alters E-cadherin/β-catenin complex interactions.
MCF7 (M), Cd7 (7) and Cd12 (12) were harvested forco-immunoprecipitation (co-IP) and total
cell lysates were immunoprecipitated with α-E-cadherin. β-catenin/E-cadherin interactions
were analyzed by Western blot analysis.
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cadherin (green) and -catenin (red); however, the distribution of the two proteins 
is dramatically different.  In parental MCF7 cells, both E-cadherin and -catenin 
are primarily co-localized to the plasma membrane (merged- yellow) with low 
levels found in the cytoplasm; in Cd7 and Cd12 cells, lower levels of E-cadherin 
and  -catenin are found in the plasma membrane. The -catenin that is found 
near the plasma membrane is not as well-organized as that which is observed in 
the parental MCF7 cells. Consistent with these observations, the Cd7 and C12 
cells are morphologically different, with individual cells farther apart and 
displaying fewer cell-cell interactions in comparison to parental cells (Fig. 4).   
As mentioned earlier, in addition to the membrane-localized form of -
catenin, the active form of -catenin is primarily localized to the nucleus where it 
regulates gene expression.  To examine how changes in the E-cadherin protein 
levels and distribution alter the active form of -catenin, we used 
immunofluorescence to monitor the localization of the active form of -catenin in 
the various cells. Results in Figure 5 show that cadmium-adapted cells (Cd7 and 
Cd12) display elevated levels of active -catenin (green) in the nucleus in 
comparison to parental MCF-7 cells, suggesting that changes in expression of 
genes associated with chronic cadmium exposure may be associated with the 
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Figure 4: Prolonged cadmium exposure disrupts E-cadherin/β-catenin complex. Protein localization of E-cadherin and β-catenin was










Figure 5: Active β-catenin localizes in the nucleus of prolonged cadmium exposed cells.
Protein localization of active β-catenin was analyzed in MCF-7, Cd7 and Cd12 cells using





3.4 Discussion  
E-cadherin is known as a tumor suppressor protein and is used as a 
prognostic marker for breast cancer (Heimann et al. 2000, Baranwal and Alahari 
2009). Results from this study show that cadmium disrupts cell-to-cell adhesion 
by down-regulating E-cadherin at the protein level (Fig. 1). Down-regulation of E-
cadherin has been associated with more aggressive breast cancers and poor 
prognosis (Mohammadizadeh et al. 2009, Oka et al. 1993).   Consistent with a 
recent study by Chakraborty et al. which showed that acute treatments of 
cadmium were able to disrupt E-cadherin/-catenin junction complex and 
degrade E-cadherin in kidney tubule cells (Chakraborty et al. 2010), we 
demonstrated that both acute cadmium and estrogen exposure lead to the down-
regulation of E-cadherin protein (Fig. 2). Several studies have shown that 
estrogen can induce the down-regulation and degradation of E-cadherin and the 
process has been shown to be mediated through ER (Oesterreich et al. 2003, 
Cardamone et al. 2009, Potter et al. 1996, Park et al. 2008).  Since cadmium 
functions as a metalloestrogen, the observation that both acute and chronic 
cadmium exposures likewise down-regulate E-cadherin is not surprising.  
Most importantly, we showed that chronic cadmium exposure promotes the 
down-regulation of E-cadherin and significantly alters the interaction of E-
cadherin with -catenin. Using co-immunoprecipitation assays, results show that 
indeed fewer -catenin molecules were complexed with E-cadherin in cadmium 
cells (Cd7 and Cd12) in comparison to the parental MCF7 cells. Once E-cadherin 





-catenin may translocate to the nucleus and cross-talk with other transcription 
factors to modulate expression of genes (Chakraborty et al. 2010, Lin et al. 2000, 
He et al. 1998, Li et al. 1999, Mann et al. 1999), including c-myc and cyclin D1, 
which been shown to be elevated in cadmium exposed cells (Siewit et al. 2010, 
Chakraborty et al. 2010, Benbrahim-Tallaa et al. 2009). Immunofluorescence 
microscopy supported this speculation by revealing altered distribution patterns 
of E-cadherin and -catenin in cells chronically exposed to cadmium.  Lower 
levels of E-cadherin and -catenin were found in the plasma membrane of 
cadmium-treated cells, and there were elevated levels of active -catenin in the 
nucleus.  We contend that -catenin, once freed from the E-cadherin adhesion 
complex, can localize into the nucleus where it regulates transcription by  
interacting with transcription factors such as the T-cell factor-4 (TCF-4) or 
lymphoid enhancer factor-1 (LEF-1), thus activating target genes and the Wnt 
signaling pathway (Lin et al. 2000, Chakraborty et al 2010).  
In short, we propose that results from this study demonstrate that prolonged 
cadmium exposure disrupts cell-cell adhesion by down-regulating E-cadherin 
expression and relocating active -catenin to the nucleus. This in turn mediates 
the increased invasive and metastatic properties associated with chronic 
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Our research has provided an original contribution to the field of breast 
cancer progression. Specifically, we have demonstrated two possible 
mechanisms of cadmium carcinogenesis (Chapters 2 and 3). Unlike most studies 
that have focused on the effects of acute cadmium exposure on breast cancer, 
our study largely focused on the effects of chronic cadmium exposure on breast 
cancer progression. In order to begin to understand the effects of chronic 
cadmium exposure on breast cancer progression, we developed several MCF7 
clonal cell lines that were exposed to low concentrations of cadmium for a 
prolonged period of time (6 months).  Using this model system, we evaluated the 
impacts of this exposure on breast cancer progression. Results from this work 
not only demonstrated that prolonged exposure to cadmium increases cell 
proliferation through the activation of ER— as seen in most acute studies— but 
also results in the acquisition of more aggressive cancer phenotypes. 
Our findings in Chapter 2 show that cells chronically exposed to cadmium 
display an increased ability to proliferate, migrate and invade when compared to 
the parental MCF7 cell line.  Further analysis revealed that chronic cadmium 
exposure stimulated cells to express higher levels of SDF-1, a chemokine often 
associated with tumor invasion and metastasis.  We also provided several lines 
of evidence suggesting that the expression of SDF-1 is not only dependent on 
the levels of ER, but also on its interaction with c-jun/c-fos heterodimers. The 
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findings presented here suggest that chronic cadmium exposure promotes 
migration and invasion by altering the molecular interactions of ER, c-jun and c-
fos and subsequent transcriptional machinery to up-regulate SDF-1 expression.   
While SDF-1 is an important contributor of metastasis, there are likely 
other factors that participate in this process and facilitate the transformation to a 
more malignant phenotype. In Chapter 3, we revealed that chronic exposure to 
cadmium also alters the expression of two crucial cell-cell adhesion molecules, 
E-cadherin and -catenin. More specifically, cells chronically exposed to 
cadmium expresses lower levels of E-cadherin at the protein level.  Since no 
changes are observed at the transcriptional level, this suggests that cadmium 
exposure promotes the down-regulation of the E-cadherin protein. The 
consequence of losing E-cadherin is two fold—(1) decrease in cell-cell adhesion 
and (2) redistribution of -catenin into the nucleus where it alters gene 
expression to stimulate breast cancer progression. 
In summary, the research presented here has demonstrated that chronic 
cadmium exposure facilitates the progression of breast cancer by mediating 
molecular changes that alter cancer cells’ ability to migrate and invade.  While 
this work has made significant advancements in the understanding of how 
environmental contaminants such as cadmium promote breast cancer 
progression, it also warrants the need for further research in this area to help us 
truly understand cadmium carcinogenesis. 
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